| 1 |
Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis [J]. Am J Respir Crit Care Med, 2016, 193(3): 259-272.
|
| 2 |
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) [J]. JAMA, 2016, 315(8): 801-810.
|
| 3 |
Sakr Y, Jaschinski U, Wittebole X, et al. Sepsis in intensive care unit patients: worldwide data from the intensive care over nations audit [J]. Open Forum Infect Dis, 2018, 5(12): 313.
|
| 4 |
Weng L, Zeng XY, Yin P, et al. Sepsis-related mortality in China: a descriptive analysis [J]. Intensive Care Med, 2018, 44(7): 1071-1080.
|
| 5 |
Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era [J]. Haematologica, 2020, 105(2): 260-272.
|
| 6 |
Gulec S, Anderson GJ, Collins JF. Mechanistic and regulatory aspects of intestinal iron absorption [J]. Am J Physiol Gastrointest Liver Physiol, 2014, 307(4): 397-409.
|
| 7 |
Dong XP, Cheng X, Mills E, et al. The type Ⅳ mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel [J]. Nature, 2008, 455(7215): 992-996.
|
| 8 |
Gunshin H, Mackenzie B, Berger UV, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter [J]. Nature, 1997, 388(6641): 482-488.
|
| 9 |
McKie AT, Marciani P, Rolfs A, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation [J]. Mol Cell, 2000, 5(2): 299-309.
|
| 10 |
Osaki S, Johnson DA, Frieden E. The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum [J]. J Biol Chem, 1966, 241(12): 2746-2751.
|
| 11 |
Lu JP, Hayashi K, Awai M. Transferrin receptor expression in normal, iron-deficient and iron-overloaded rats [J]. Acta Pathol Jpn, 1989, 39(12): 759-764.
|
| 12 |
Li Y, Feng D, Wang Z, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion [J]. Cell Death Differ, 2019, 26(11): 2284-2299.
|
| 13 |
von Haehling S, Jankowska EA, van Veldhuisen DJ, et al. Iron deficiency and cardiovascular disease [J]. Nat Rev Cardiol, 2015, 12(11): 659-669.
|
| 14 |
Ganz T. Iron and infection [J]. Int J Hematol, 2018, 107(1): 7-15.
|
| 15 |
Toyokuni S. Role of iron in carcinogenesis: cancer as a ferrotoxic disease [J]. Cancer Sci, 2009, 100(1): 9-16.
|
| 16 |
Tacke F, Nuraldeen R, Koch A, et al. Iron parameters determine the prognosis of critically ill patients [J]. Crit Care Med, 2016, 44(6): 1049-1058.
|
| 17 |
Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide [J]. Proc Natl Acad Sci U S A, 1990, 87(4): 1620-1624.
|
| 18 |
吴勤英. 氧化应激水平与脓毒症患者预后的关系 [J]. 中国综合临床, 2013, 29(8): 799-802.
|
| 19 |
Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis [J]. Kidney Int, 2004, 65(6): 2108-2112.
|
| 20 |
Galleano M, Simontacchi M, Puntarulo S. Nitric oxide and iron: effect of iron overload on nitric oxide production in endotoxemia [J]. Mol Aspects Med, 2004, 25(1-2): 141-154.
|
| 21 |
Javadi P, Buchman TG, Stromberg PE, et al. High-dose exogenous iron following cecal ligation and puncture increases mortality rate in mice and is associated with an increase in gut epithelial and splenic apoptosis [J]. Crit Care Med, 2004, 32(5): 1178-1185.
|
| 22 |
Kruszewski M. Labile iron pool: The main determinant of cellular response to oxidative stress [J]. Mutat Res, 2003, 531(1-2): 81-92.
|
| 23 |
Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation [J]. Biochim Biophys Acta, 1996, 1275(3): 161-203.
|
| 24 |
Knovich MA, Storey JA, Coffman LG, et al. Ferritin for the clinician [J]. Blood Rev, 2009, 23(3): 95-104.
|
| 25 |
Garcia PC, Longhi F, Branco RG, et al. Ferritin levels in children with severe sepsis and septic shock [J]. Acta Paediatr, 2007, 96(12): 1829-1831.
|
| 26 |
Bullen JJ, Rogers HJ, Spalding PB, et al. Iron and infection: the heart of the matter [J]. FEMS Immunol Med Microbiol, 2005, 43(3): 325-330.
|
| 27 |
Darveau M, Denault AY, Blais N, et al. Bench-to-bedside review: iron metabolism in critically ill patients [J]. Crit Care, 2004, 8(5): 356-362.
|
| 28 |
Ruddell RG, Hoang-Le D, Barwood JM, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells [J]. Hepatology, 2009, 49(3): 887-900.
|
| 29 |
Moss D, Fargion S, Fracanzani AL, et al. Functional roles of the ferritin receptors of human liver, hepatoma, lymphoid and erythroid cells [J]. J Inorg Biochem, 1992, 47(3-4): 219-227.
|
| 30 |
Wang W, Knovich MA, Coffman LG, et al. Serum ferritin: Past, present and future [J]. Biochim Biophys Acta, 2010, 1800(8): 760-769.
|
| 31 |
Rosário C, Zandman-Goddard G, Meyron-Holtz EG, et al. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome [J]. BMC Med, 2013, 11: 185.
|
| 32 |
Zarjou A, Black LM, McCullough KR, et al. Ferritin light chain confers protection against sepsis-induced inflammation and organ injury [J]. Front Immunol, 2019, 10: 131.
|
| 33 |
常春康, 张曦, 肖超, 等. 铁调素的表达与调节机制研究进展 [J]. 中国实验血液学杂志, 2012, 20(4): 1030-1033.
|
| 34 |
Ganz T, , Nemeth E. Imports iron. Ⅳ. Hepcidin and regulation of body iron metabolism [J]. Am J Physiol Gastrointest Liver Physiol, 2006, 290(2): 199-203.
|
| 35 |
Nicolae CD, Coman OA, Ene C, et al. Hepcidin in neoplastic disease [J]. J Med Life, 2013, 6(3): 355-360.
|
| 36 |
Cizmeci MN, Kara S, Kanburoglu MK, et al. Detection of cord blood hepcidin levels as a biomarker for early-onset neonatal sepsis [J]. Med Hypotheses, 2014, 82(3): 310-312.
|
| 37 |
Kemna E, Pickkers P, , Nemeth E, et al. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS [J]. Blood, 2005, 106(5): 1864-1866.
|
| 38 |
van Eijk LT, Kroot JJ, Tromp M, et al. Inflammation-induced hepcidin-25 is associ-ated with the development of anemia in septic patients: An observational study [J]. Crit Care, 2011, 15(1): R9.
|
| 39 |
Zeng C, Chen Q, Zhang K,et al. Hepatic hepcidin protects against polymicrobial sepsis in mice by regulating host iron status [J]. Anesthesiology, 2015, 122(2): 374-386.
|
| 40 |
Kothary V, Doster RS, Rogers LM, et al. Group B Streptococcus induces neutrophil recruitment to gestational tissues and elaboration of extracellular traps and nutritional immunity [J]. Front Cell Infect Microbiol, 2017, 7: 19.
|
| 41 |
Halder lD, Abdelfatah MA, Jo EA, et al. Factor H binds to extracellular DNA traps released from human blood monocytes in response to Candida albicans [J]. Front Immunol, 2017, 7: 671.
|
| 42 |
Iglesias-Figueroa B, Valdiviezo-Godina N, Siqueiros-Cendón T, et al. High-level expression of recombinant bovine lactoferrin in pichia pastoris with antimicrobial activity [J]. Int J Mol Sci, 2016, 17(6): 902.
|
| 43 |
Bruns T, Nuraldeen R, Mai M, et al. Low serum transferrin correlates with acute-on-chronic organ failure and indicates short-term mortality in decompensated cirrhosis [J]. Liver Int, 2017, 37(2): 232-241.
|
| 44 |
Valenti A, Antonini G. Lactoferrin: an important host defense against microbial and viral attack [J]. Cell Mol Life Sci, 2005, 62(22): 2576-2587.
|
| 45 |
Legrand D, Pierce A, Elass E, et al. Lactoferrin structure and functions [J]. Adv Exp Med Biol, 2008, 606: 163-94.
|
| 46 |
Baveye S, Elass E, Mazurier J, et al. Lactoferrin: A multifunctional glycoprotein involved in the modulation of the inflammatory process [J]. Clin Chem Lab Med, 1999, 37(3): 281-286.
|
| 47 |
Legrand D, Elass E, Carpentier M, et al. Lactoferrin: a modulator of immune and inflammatory responses [J]. Cell Mol Life Sci, 2005, 62(22): 2549-2559.
|
| 48 |
Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway [J]. Cytokine,2008, 42(2): 145-151.
|
| 49 |
Kruzel ML, Harari Y, Mailman D, et al. Differential effects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice [J]. Clin Exp Immunol, 2002, 130(1): 25-31.
|
| 50 |
Wang C, Yuan W, Hu A, et al. Dexmedetomidine alleviated sepsisinduced myocardial ferroptosis and septic heart injury [J]. Mol Med Rep, 2020, 22(1): 175-184.
|
| 51 |
Duvigneau JC, Piskernik C, Haindl S, et al. A novel endotoxin-induced pathway: upregulation of heme oxygenase 1, accumulation of free iron, and free iron-mediated mitochondrial dysfunction [J]. Lab Invest, 2008, 88(1): 70-77.
|
| 52 |
Schwartzman ML, Abraham NG, Carroll MA, et al. Regulation of arachidonic acid metabolism by cytochrome P-450 in rabbit kidney [J]. Biochem J, 1986, 238(1): 283-290.
|
| 53 |
Fang S, Zhuo Z, Yu X, et al. Oral administration of liquid iron preparation containing excess iron induces intestine and liver injury, impairs intestinal barrier function and alters the gut microbiota in rats [J]. J Trace Elem Med Biol, 2018, 47: 12-20.
|
| 54 |
Trinder D, Fox C, Vautier G, et al. Molecular pathogenesis of iron overload [J]. Gut, 2002, 51(2): 290-295.
|
| 55 |
Rao RK, Baker RD, Baker SS, et al. Oxidant-induced disruption of intestinal epithelial barrier function: role of protein tyrosine phosphorylation [J]. Am J Physiol, 1997, 273(4): 812-823.
|
| 56 |
Rao RK, Basuroy S, Rao VU, et al. Tyrosine phosphorylation and dissociation of occludin-ZO-1 and E-cadherin-beta-catenin complexes from the cytoskeleton by oxidative stress [J]. Biochem J, 2002, 368(2): 471-481.
|
| 57 |
Zhang V, Ganz T, Nemeth E, et al. Iron overload causes a mild and transient increase in acute lung injury [J]. Physiol Rep, 2020, 8(12): 14470.
|
| 58 |
Deschemin JC, Mathieu JRR, Zumerle S, et al. Pulmonary Iron Homeostasis in Hepcidin Knockout Mice [J]. Front Physiol, 2017, 8: 804.
|
| 59 |
Wang C, Yuan W, Hu A, et al. Dexmedetomidine alleviated sepsisinduced myocardial ferroptosis and septic heart injury [J]. Mol Med Rep, 2020, 22(1): 175-184.
|
| 60 |
Hardang IM, Lilleholt K, Hagve TA. Anemi ved kronisk sykdom [J]. Tidsskr Nor Laegeforen, 2017, 137(17): 10.
|
| 61 |
Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer [J]. Pharmacol Rev, 2005, 57(4): 547-583.
|
| 62 |
Dragset MS, Poce G, Alfonso S, et al. A novel antimycobacterial compound acts as an intracellular iron chelator [J]. Antimicrob Agents Chemother, 2015, 59(4): 2256-2264.
|
| 63 |
Vlahakos D, Arkadopoulos N, Kostopanagiotou G, et al. Deferoxamine attenuates lipid peroxidation, blocks interleukin-6 production, ameliorates sepsis inflammatory response syndrome, and confers renoprotection after acute hepatic ischemia in pigs [J]. Artif Organs, 2012, 36(4): 400-408.
|
| 64 |
Cermanova J, Kadova Z, Dolezelova E, et al. Deferoxamine but not dexrazoxane alleviates liver injury induced by endotoxemia in rats [J]. Shock, 2014, 42(4): 372-379.
|
| 65 |
Vulcano M, Meiss RP, Isturiz MA. Deferoxamine reduces tissue injury and lethality in LPS-treated mice [J]. Int J Immunopharmacol, 2000, 22(8): 635-644.
|
| 66 |
Messaris E, Antonakis PT, Memos N, et al. Deferoxamine administration in septic animals: improved survival and altered apoptotic gene expression [J]. Int Immunopharmacol, 2004, 4(3): 455-459.
|
| 67 |
Bullen JJ, Rogers HJ, Spalding PB, et al. Iron and infection: the heart of the matter [J]. FEMS Immunol Med Microbiol, 2005, 43(3): 325-330.
|
| 68 |
van Eijk LT, Heemskerk S, van der Pluijm RW, et al. The effect of iron loading and iron chelation on the innate immune response and subclinical organ injury during human endotoxemia: a randomized trial [J]. Haematologica, 2014, 99(3): 579-587.
|
| 69 |
Scindia Y, Wlazlo E, Leeds J, et al. Protective Role of Hepcidin in Polymicrobial Sepsis and Acute Kidney Injury [J]. Front Pharmacol, 2019, 10: 615.
|
| 70 |
Ellison RT, Giehl TJ, LaForce FM. Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin [J]. Infect Immun, 1988, 56(11): 2774-2781.
|
| 71 |
Guntupalli K, Dean N, Morris PE, et al. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis [J]. Crit Care Med, 2013, 41(3): 706-716.
|
| 72 |
Vincent JL, Marshall JC, Dellinger RP, et al. Talactoferrin in severe sepsis: results from the phase Ⅱ/Ⅲ oral tAlactoferrin in severe sepsis trial [J]. Crit Care Med, 2015, 43(9): 1832-1838.
|